CRISPR Therapeutics AG (CRSP) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Halozyme Therapeutics, Inc.

10X Genomics, Inc.

Illumina, Inc.

Bio-Techne Corp.

BioMarin Pharmaceutical, Inc.

Elanco Animal Health, Inc.

BridgeBio Pharma, Inc.

CRISPR Therapeutics AG

ImmunoGen, Inc.

Vaxcyte, Inc.

Immunovant, Inc.

Why is CRISPR Therapeutics AG ?

Poor Management Efficiency with a low ROE of 3.15%

The company has been able to generate a Return on Equity (avg) of 3.15% signifying low profitability per unit of shareholders funds

The company has declared negative results for the last 4 consecutive quarters

NET SALES(HY) At USD 1.75 MM has Grown at -95.17%
OPERATING CASH FLOW(Y) Lowest at USD -345.01 MM
ROCE(HY) Lowest at -30.18%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 16.10%, its profits have fallen by -39.8%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is CRISPR Therapeutics AG for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

CRISPR Therapeutics AG

16.1%

-0.29

64.15%

S&P 500

20.12%

1.04

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

30.54%

EBIT Growth (5y)

-16.89%

EBIT to Interest (avg)

-271.84

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.07

Tax Ratio

1.04%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

90.57%

ROCE (avg)

229.94%

ROE (avg)

3.15%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.94

EV to EBIT

-11.03

EV to EBITDA

-11.51

EV to Capital Employed

1143.88

EV to Sales

132.31

PEG Ratio

Dividend Yield

ROCE (Latest)

-10366.12%

ROE (Latest)

-21.71%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -248.25 MM

DEBT-EQUITY RATIO (HY)

Lowest at -92.45 %

-28What is not working for the Company

NET SALES(HY)

At USD 1.75 MM has Grown at -95.17%

OPERATING CASH FLOW(Y)

Lowest at USD -345.01 MM

ROCE(HY)

Lowest at -30.18%

RAW MATERIAL COST(Y)

Grown by 8,026.76% (YoY

OPERATING PROFIT(Q)

Lowest at USD -149.1 MM

PRE-TAX PROFIT(Q)

Lowest at USD -135.7 MM

NET PROFIT(Q)

Lowest at USD -136.31 MM

Here's what is working for CRISPR Therapeutics AG

Debt-Equity Ratio

Lowest at -92.45 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Depreciation

Highest at USD 5.66 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Depreciation

At USD 5.66 MM has Grown at 28.66%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (USD MM)

Here's what is not working for CRISPR Therapeutics AG

Net Sales

At USD 1.75 MM has Grown at -95.17%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -135.7 MM has Fallen at -37.83%

over average net sales of the previous four periods of USD -98.46 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -136.31 MM has Fallen at -37.16%

over average net sales of the previous four periods of USD -99.39 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -345.01 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -149.1 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -135.7 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -136.31 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Raw Material Cost

Grown by 8,026.76% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales